Neurodegenerative disease management最新文献

Mapping care interventions for people living with motor neurone disease: a living evidence and gap map. 绘制运动神经元疾病患者的护理干预措施：活证据和缺口图。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-18 DOI: 10.1080/17582024.2026.2749397

Danielle Pollock, Nipun Shrestha, Sebastian Cole Facchin-Young, Anna Fragkoudi, Abigail Molly Day-Sharman, Lemma Negesa Bulto, Melissa Bond, Cindy Stern, Timothy Hugh Barker, Sabira Hasanoff, Grace Holland, Ines Semendric, Lara Stollery, Sitasma Sharma, Yogeeta Viswanath Harish, Camille Schubert, Lynne Giles, Jay Beasley-Hall, Tracy Merlin, Julie Labra, Steve Vucic, Taryn Hunt, Zachary Munn

{"title":"Mapping care interventions for people living with motor neurone disease: a living evidence and gap map.","authors":"Danielle Pollock, Nipun Shrestha, Sebastian Cole Facchin-Young, Anna Fragkoudi, Abigail Molly Day-Sharman, Lemma Negesa Bulto, Melissa Bond, Cindy Stern, Timothy Hugh Barker, Sabira Hasanoff, Grace Holland, Ines Semendric, Lara Stollery, Sitasma Sharma, Yogeeta Viswanath Harish, Camille Schubert, Lynne Giles, Jay Beasley-Hall, Tracy Merlin, Julie Labra, Steve Vucic, Taryn Hunt, Zachary Munn","doi":"10.1080/17582024.2026.2749397","DOIUrl":"https://doi.org/10.1080/17582024.2026.2749397","url":null,"abstract":"Motor neurone disease (MND) is a debilitating, life-limiting neurodegenerative disease that has no cure. Caring for a person living with MND requires a multidisciplinary team delivering interventions to address symptoms. We aimed to map evidence supporting care of those living with MND. Evidence and gap maps (EGMs) were developed according to Campbell and JBI guidance for scoping reviews. Databases searched included CENTRAL, MEDLINE, EMBASE, and PsycINFO with no date restriction. Articles describing care interventions for people living with MND, carers, asymptomatic genetic carriers, family, friends, and healthcare professionals were included. 2390 reports were drawn from 1594 articles that were included across five EGMs, supportive and symptom management (n = 673 articles), pharmacological (n = 592), models of care (n = 196), medical and clinical interventions (n = 185), and technology and equipment (n = 91). Interventions primarily addressed people who are living with MND (n = 1732). No articles were identified specifically concerning First Nations Peoples, Culturally and Linguistically Diverse Peoples, or those living in remote, rural or regional areas. MND care interventions are diverse. Further research is needed to understand options for Culturally and Linguistically Diverse Peoples, First Nations Peoples, and those living in rural, regional, and remote communities.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aqueous extracts of Phyllanthus amarus leaf mitigate cognitive impairments by enhancing neurotransmitter regulation and antioxidant defense mechanisms. 毛茛叶水提物通过增强神经递质调节和抗氧化防御机制减轻认知障碍。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-08 DOI: 10.1080/17582024.2026.2744198

Bukola Christiana Adedayo, Idowu Sunday Oyeleye, Olayinka Sakiru Oyelami, Olayemi Philemon Aro, Olajide Raymond Ojo, Ganiyu Oboh

{"title":"Aqueous extracts of Phyllanthus amarus leaf mitigate cognitive impairments by enhancing neurotransmitter regulation and antioxidant defense mechanisms.","authors":"Bukola Christiana Adedayo, Idowu Sunday Oyeleye, Olayinka Sakiru Oyelami, Olayemi Philemon Aro, Olajide Raymond Ojo, Ganiyu Oboh","doi":"10.1080/17582024.2026.2744198","DOIUrl":"https://doi.org/10.1080/17582024.2026.2744198","url":null,"abstract":"Aims: Phyllanthus amarus (PA, P. amarus), commonly known as stonebreaker, has historically been used in traditional medicine for its medicinal attributes. Cognitive impairment continues to pose a major challenge in neurodegenerative disorders, with natural products being extensively explored as potential therapies. This study examined the effects of aqueous leaf extracts P. amarus on cognitive behaviors and neurochemical markers in scopolamine-induced amnesic rats.Material and methods: Rats were administered aqueous PA extracts (50 and 500 mg/kg) or donepezil for a duration of 14 days. Cognitive performance was assessed through behavioral tests followed by neurochemical evaluation of cholinesterases (ChEs), monoamine oxidase (MAO), and purinergic enzymes in the cortex and hippocampus of the rats' brains.Results: Administration of scopolamine impaired learning and memory and disrupted biochemical homeostasis. Treatment with PA extract significantly improved cognitive performance and attenuated scopolamine-induced alterations in neurotransmitter activity and oxidative stress markers.Conclusion: In conclusion, aqueous leaf extracts of PA treatment may provide a new potential alternative for the treatment and prevention of cognitive impairment and neurochemical changes associated with neurotoxic agents, suggesting its potential to ameliorate scopolamine‑induced cognitive impairment and neurochemical alterations, while further studies are required to establish relevance to Alzheimer's disease pathology.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual targeting of melatonergic and serotonergic neurotransmissions in Parkinson's disease: role of agomelatine. 帕金森病中褪黑激素和血清素能神经传递的双重靶向：阿戈美拉汀的作用。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-08 DOI: 10.1080/17582024.2026.2744191

Hayder M Al-Kuraishy, Marwa Thaier Naji, Raghad Rahem Abd Hasan, Duaa Eliwa, Gaber El-Saber Batiha

{"title":"Dual targeting of melatonergic and serotonergic neurotransmissions in Parkinson's disease: role of agomelatine.","authors":"Hayder M Al-Kuraishy, Marwa Thaier Naji, Raghad Rahem Abd Hasan, Duaa Eliwa, Gaber El-Saber Batiha","doi":"10.1080/17582024.2026.2744191","DOIUrl":"https://doi.org/10.1080/17582024.2026.2744191","url":null,"abstract":"Parkinson's disease (PD) is a progressive neurodegenerative disorder of the central nervous system (CNS), driven by the pathological aggregation and accumulation of α-synuclein (α-Syn) within dopaminergic neurons of the substantia nigra pars compacta (SNpc). Despite extensive research, the pathogenesis of PD remains incompletely understood and involves complex molecular signaling pathways. Melatonin and serotonin are dysregulated in PD and may contribute to cognitive impairment, sleep disturbances, and neuropsychiatric manifestations. Accordingly, restoration of melatonergic and serotonergic neurotransmission may support the management of depressive symptoms, cognitive impairment, and sleep disorders in patients with PD. Agomelatine, used in the management of major depressive disorder, can modulate both melatonergic and serotonergic neurotransmission. However, its molecular mechanisms and potential effects on the development and progression of PD have not been comprehensively evaluated. A literature search was conducted using PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar from database inception to July 2026, using relevant keywords and MeSH terms related to PD, melatonergic and serotonergic neurotransmission, and agomelatine. Therefore, this narrative review discusses the role of melatonergic and serotonergic neurotransmission in PD and examines how targeting these pathways with agomelatine may contribute to PD management.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular and genetic basis of alzheimer's disease and emerging treatment Modalities. 阿尔茨海默病的分子和遗传基础及新出现的治疗方式。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-02 DOI: 10.1080/17582024.2026.2739332

Himanshi Varshney, Yasir Hasan Siddique

{"title":"Molecular and genetic basis of alzheimer's disease and emerging treatment Modalities.","authors":"Himanshi Varshney, Yasir Hasan Siddique","doi":"10.1080/17582024.2026.2739332","DOIUrl":"https://doi.org/10.1080/17582024.2026.2739332","url":null,"abstract":"Background: Alzheimer's disease (AD) is linked to various causes and pathological processes. It represents a major global health challenge due to its increasing prevalence in aging populations. AD involves multifactorial pathological mechanisms. Two different forms of AD defined by changes in specific genes like APOE4, CLU, TREM2, PICALM, BIN1, MS4A, CR1, ABCA7 and APH1B. Apart from specific genetic mutations, there are multiple risk factors such as aging, obesity, lifestyle, head injury, drinking, smoking and environmental factors that further influence disease risk and its progression.Methods: The literature of this review article was taken from different search engines viz. Pubmed, Google Scholar and Scopus, explaining modifiable contributing factors and prognostic markers, including the genetics of AD and overall, this review analyzes literature published between 2000 to 2025 to summarizes the current status of disease, highlighting its importance for improving diagnosis, prognosis, and the development of targeted therapeutic strategies.Result: There are multiple contributing factors in both the disease mechanism and development of AD, apart from amyloid hypothesis and neurofibrillary tangles.Discussion: A strategic analysis and targeted treatment of these contributing factors could help mitigate the progression of AD and offer potential protective benefits.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-21"},"PeriodicalIF":2.8,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathology of Friedreich ataxia and its links to metabolic pathways. 弗里德赖希共济失调的神经病理学及其与代谢途径的联系。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2025-12-25 DOI: 10.1080/17582024.2025.2607957

Elizabeth Mercado-Ayón, Michael P Lazaropoulos, Yesica Mercado-Ayón, David R Lynch

{"title":"Neuropathology of Friedreich ataxia and its links to metabolic pathways.","authors":"Elizabeth Mercado-Ayón, Michael P Lazaropoulos, Yesica Mercado-Ayón, David R Lynch","doi":"10.1080/17582024.2025.2607957","DOIUrl":"10.1080/17582024.2025.2607957","url":null,"abstract":"Frataxin is an evolutionarily conserved mitochondrial protein essential for energy metabolism. Biallelic GAA repeat expansions in the FXN gene reduce frataxin expression, causing Friedreich's ataxia. Frataxin deficiency impairs key mitochondrial metabolic enzymes, leading to widespread mitochondrial dysfunction with disrupted glucose and fatty acid oxidation. Although systemic mitochondrial dysfunction affects multiple organ systems, neurological deficits are the only feature uniformly observed in all FRDA patients. This review highlights recent insights into the neuropathology of FRDA, emphasizing the detailed developmental timing of neuroanatomical changes. It also focuses on selective mitochondrial metabolic pathways, including fatty acid metabolism, ceramide synthesis, and ketogenesis, which may underlie neuron-specific vulnerability and serve as potential targets for pharmacological or dietary intervention. The possibility of non-traditional interventions based on metabolic features of FRDA offers hope for ameliorating the severity of FRDA.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"619-630"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guidelines addressing Motor Neurone Disease (MND): a scoping review. 运动神经元疾病（MND）指南：范围综述

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2025-11-03 DOI: 10.1080/17582024.2025.2573608

Cindy Stern, Ines Semendric, Nipun Shrestha, Jay Beasley-Hall, Sabira Hasanoff, Timothy Barker, Danielle Pollock, Camille Schubert, Lynne Giles, Steve Vucic, Tracy Merlin, Zachary Munn

{"title":"Guidelines addressing Motor Neurone Disease (MND): a scoping review.","authors":"Cindy Stern, Ines Semendric, Nipun Shrestha, Jay Beasley-Hall, Sabira Hasanoff, Timothy Barker, Danielle Pollock, Camille Schubert, Lynne Giles, Steve Vucic, Tracy Merlin, Zachary Munn","doi":"10.1080/17582024.2025.2573608","DOIUrl":"10.1080/17582024.2025.2573608","url":null,"abstract":"Introduction: Motor Neurone Disease (MND) is a debilitating neurodegenerative condition affecting individuals, families, and carers. Evidence-informed care can improve outcomes, and guidelines play a key role in supporting this. A preliminary search showed limited guidelines exist, with none developed for the Australian context. This review aimed to identify existing health and social care guidelines for MND.Methods: A scoping review was conducted using Joanna Briggs Institute (JBI) methodology. Guidelines addressing health and social care for people with MND, gene carriers, family members, or carers were included regardless of publication status. Five databases and additional sources were searched. Two reviewers independently screened citations, and data were extracted and analysed descriptively, with qualitative content analysis grouping guideline questions. Reporting followed PRISMA-ScR.Results: Forty-two guidelines covering 133 questions were included. Most focused on symptom management for people with MND and were produced by professional bodies. Few used GRADE methodology or systematic reviews, and only seven assessed risk of bias. No guideline was developed for Australia.Conclusions: A high-quality, evidence-based MND guideline following best practice development methods is needed.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"603-618"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145431760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The underlying causes of eye movement disorders and ataxia. 眼动障碍和共济失调的根本原因。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2025-10-31 DOI: 10.1080/17582024.2025.2578963

Nannan Qian, Chengcheng Lu, Yufei Qian, Wenming Yang, Taohua Wei

引用次数: 0

N-acetylcysteine for Parkinson's disease: a translational systematic review of mechanistic and early clinical data. n -乙酰半胱氨酸治疗帕金森病：机制和早期临床数据的翻译系统综述。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2025-09-24 DOI: 10.1080/17582024.2025.2563489

Anas Mohammad, Mohammad Ibrahim, Moeez Akram, Hadia Mohsin, Muhammad Taaib Imran, Hassam Nasir Khan Alizai

{"title":"N-acetylcysteine for Parkinson's disease: a translational systematic review of mechanistic and early clinical data.","authors":"Anas Mohammad, Mohammad Ibrahim, Moeez Akram, Hadia Mohsin, Muhammad Taaib Imran, Hassam Nasir Khan Alizai","doi":"10.1080/17582024.2025.2563489","DOIUrl":"10.1080/17582024.2025.2563489","url":null,"abstract":"Background: Parkinson's disease (PD) involves progressive motor and non-motor decline, linked to oxidative stress and glutathione depletion. N-acetylcysteine (NAC), a glutathione precursor and antioxidant, is a potential disease-modifying therapy.Objective: To evaluate preclinical and clinical evidence on NAC in PD, focusing on motor and non-motor outcomes, dopaminergic function, and oxidative stress biomarkers.Methods: A PRISMA-compliant review of MEDLINE and Embase (May 2025) identified prospective studies in animal models or adults with PD. Outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), dopamine transporter (DAT) imaging, glutathione levels, and safety.Results: Twelve studies met criteria. Preclinical models showed consistent neuroprotection. Intravenous NAC raised brain glutathione levels; high-dose oral NAC reached CSF. Two open-label trials (n = 65), reported ~ 13% improvement in UPDRS scores and 4-9% dopamine transporter signal increases over three months. No serious adverse events were attributed to NAC.Conclusions: Larger randomized controlled trials are needed to test efficacy and disease-modifying potential.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"631-642"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registered Dietitians' perspectives on nutrition management of persons living with amyotrophic lateral sclerosis. 注册营养师对肌萎缩侧索硬化症患者营养管理的看法。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2026-03-19 DOI: 10.1080/17582024.2026.2646759

Amy C Ellis, Stephanie Dobak, Keith Pearson, Rebekah McGuire, Tyler Sutton

{"title":"Registered Dietitians' perspectives on nutrition management of persons living with amyotrophic lateral sclerosis.","authors":"Amy C Ellis, Stephanie Dobak, Keith Pearson, Rebekah McGuire, Tyler Sutton","doi":"10.1080/17582024.2026.2646759","DOIUrl":"10.1080/17582024.2026.2646759","url":null,"abstract":"Aim: Persons with amyotrophic lateral sclerosis (PALS) are at high risk for malnutrition, which is a negative prognostic factor for disease progression and survival. This study explored the perspectives of Registered Dietitians (RDs) providing nutrition care to PALS, focusing on barriers and facilitators to optimal patient care.Methods: RDs from U.S. multidisciplinary ALS clinics participated in six virtual focus groups. Recordings were transcribed verbatim and independently coded by two researchers for deductive content analysis.Results: RDs highlighted the importance of using clinical judgment to assess nutrition status and individualizing recommendations to respect patient autonomy. The multidisciplinary team model was identified as a strong facilitator to optimal patient care, while insurance coverage for nutrition-related supplies was a common barrier. RDs reported having little prior knowledge of ALS before assuming their current roles and described the need to upskill through self-teaching and on-the-job experience.Conclusions: Results emphasize the importance of clinical judgment with respect to patient autonomy in providing nutrition care to PALS. The barriers and facilitators identified across multiple levels provide insight for future interventions to improve patient care.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"545-553"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An implementation study of a remote monitoring platform to increase access to specialist care in motor neuron disease. 增加运动神经元疾病专科护理的远程监测平台的实施研究。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2026-02-18 DOI: 10.1080/17582024.2026.2629783

Liam Knox, Polly Kennedy, Deirdre Gilsenan, Deirdre Murray, Miriam Galvin, Yasmin Ali, Orla Hardiman, Christopher McDermott, Esther Hobson

{"title":"An implementation study of a remote monitoring platform to increase access to specialist care in motor neuron disease.","authors":"Liam Knox, Polly Kennedy, Deirdre Gilsenan, Deirdre Murray, Miriam Galvin, Yasmin Ali, Orla Hardiman, Christopher McDermott, Esther Hobson","doi":"10.1080/17582024.2026.2629783","DOIUrl":"10.1080/17582024.2026.2629783","url":null,"abstract":"Introduction: The aim was to examine the engagement and acceptability of Telehealth in MND (TiM) as part of usual care within two specialist centers.Methods: Fifty people with MND (pwMND) completed questionnaires. Eight pwMND and carers participated in interviews.Results: In Shefield, 163 pwMND were invited to TiM with 52% registering and 85% engagement. In Dublin, 98 pwMND were invited to TiM, with 63% registering, and 95% engagement.High levels of acceptability were reported, with users rating TiM as very low in burden. Similar findings were demonstrated within the interviews, with ease of use a strength. However, participants discussed a need for more regular feedback from TiM. Future opportunities relating to integrating TiM with community services were discussed.Discussion: TiM is feasible and acceptable to pwMND. The high engagement can generate a wealth of data facilitating solution-focused clinical appointments. The study's findings support the further implementation of TiM in other MND services.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"535-543"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0